Floatz logo

Fruquintinib

Raltitrexed

Meng QiuSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Raltitrexed cohort.

Asset / SponsorPhaseRating
Raltitrexed
Meng Qiu
Phase 2BB
Adebrelimab
Meng Qiu
Phase 2CCC
S-1
Meng Qiu
Phase 2CCC
Regorafenib
China Medical University, China
Phase 1/2CCC

Same molecule, other indications

Fruquintinib is also rated in:

metastasis from malignant tumor of colonDormant
BBB
Indicative ·
72 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →